Nanomedicine: current status and future prospects

By S. Moghimi, A. C. Hunter, J. C. Murray. The FASEB Journal, 2005

1,940 citations recorded by the source corpus.

Subfields: Biomaterials, Biomedical Engineering, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/24818ec8d2f7024959953c80a9cfaf50d1b5527f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

In Biomedical Engineering

In Molecular Biology

Citations in the corpus

The nanosilica hazard: another variable entity (2010, background): “In addition, nanosilica is being developed for a host of biomedical and biotechnological applications such as cancer therapy, DNA transfection, drug delivery, and enzyme immobilization [5-9].”
Nanomaterials and nanoparticles: Sources and toxicity (2007, background): “Several are comparatively general [18], [20], [30-32], while others address selected aspects of nanoparticles toxicology, such as: health effects of air pollution [33]; epidemiological reviews of exposure to particles [34]; epidemiological studies of cardiovascular effects of airborne particles [35]”
Better safe than sorry: Understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. (2010, background): “Recent years have witnessed a tremendous expansion of research and potential applications of nanotechnology in medicine, including the exploitation of nanomaterials as carriers of active pharmaceutical drugs in delivery and targeting applications, and for medical imaging purposes [1].”
A review of stimuli-responsive nanocarriers for drug and gene delivery. (2008, background): “Nanoparticulate carriers can be made from a variety of organic and inorganic materials including non-degradable and biodegradable polymers, lipids (liposomes, nanoemulsions, and solid-lipid nanoparticles) self-assembling amphiphilic molecules, dendrimers, metal, and inorganic semiconductor nanocryst”
Investigating the optimal size of anticancer nanomedicine (2014, background): “In conjunction with the renal clearance threshold (<10–15 nm) (20, 21) and interstitial/lymphatic fenestration (<20 nm) (22) for NPs, it becomes essential to carefully and comprehensively evaluate the in vivo behavior and anticancer efficacy of NMs in the size range of 20–50 nm to determine the opti”
Nanomedicine for drug delivery and imaging: A promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles (2007, background): “of pharmaceutical, therapeutic, and diagnostic agents is at the forefront of projects in nanomedicine.(5,6) Nanosystems, which can be”
A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. (2005, background): “An understanding of such events may eventually help to design novel and safer materials with high transfection efficiencies suitable for clinical gene therapy as well as for controlling intracellular distribution of drugs with cationic polymer- or lipid-based delivery systems [29,30].”
Introduction to metallic nanoparticles (2010, methodology): “Table 1: Comparison of common imaging techniques along with the nanoparticles currently used or under clinical trials[10]”